BioXcel Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . BioXcel Therapeutics
BTAI Stock  USD 1.59  0.03  1.85%   
BioXcel Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioXcel Therapeutics' valuation are provided below:
Gross Profit
-212 K
Market Capitalization
34.8 M
Enterprise Value Revenue
144.3332
Revenue
752 K
Earnings Share
(9.12)
We have found one hundred twenty available fundamental signals for BioXcel Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of BioXcel Therapeutics prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 13 M. Enterprise Value is estimated to decrease to about 104.4 M

BioXcel Therapeutics Total Revenue

2.74 Million

Check BioXcel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioXcel Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 18.3 M, Selling General Administrative of 27.2 M or Other Operating Expenses of 71.8 M, as well as many indicators such as Price To Sales Ratio of 7.31, Dividend Yield of 0.0 or Days Sales Outstanding of 23.05. BioXcel financial statements analysis is a perfect complement when working with BioXcel Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with BioXcel Stock
Check out the analysis of BioXcel Therapeutics Correlation against competitors.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

BioXcel Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets41.9 M44.1 M55.6 M
Slightly volatile
Total Current Liabilities14 M25.6 M9.8 M
Slightly volatile
Common Stock Shares Outstanding1.6 M2.9 M1.4 M
Slightly volatile
Total Liabilities158.7 M151.2 M44.1 M
Slightly volatile
Total Current Assets40.9 M43 M54.6 M
Slightly volatile
Property Plant Equipment855.5 K1.2 M617.5 K
Slightly volatile
Other Current Liabilities8.3 M6.6 M4.9 M
Slightly volatile
Property Plant And Equipment Net1.5 M985.5 K870.6 K
Slightly volatile
Accounts Payable19.3 M18.4 M5.6 M
Slightly volatile
Non Current Assets Total1.7 M1.1 M997.7 K
Slightly volatile
Non Currrent Assets Other95 K100 K121.5 K
Slightly volatile
Liabilities And Stockholders Equity41.9 M44.1 M55.6 M
Slightly volatile
Other Current Assets8.1 M7.7 M2.6 M
Slightly volatile
Property Plant And Equipment Gross2 M2.7 M1.2 M
Slightly volatile
Short and Long Term Debt Total124.3 M118.4 M32.3 M
Slightly volatile
Other Assets1.091.15376.4 K
Slightly volatile
Cash And Short Term Investments32.6 M34.3 M52 M
Slightly volatile
Common Stock Total Equity22.7 K32.2 K17.9 K
Slightly volatile
Capital Surpluse589.6 M561.5 M211.9 M
Slightly volatile
Deferred Long Term Liabilities1.5 M2.7 M1.4 M
Slightly volatile
Short and Long Term Debt296.8 K333.9 K364.5 K
Slightly volatile
Short Term Debt330.6 K430.1 K330.9 K
Pretty Stable
Capital Stock30.3 K56.4 K24 K
Slightly volatile
Capital Lease Obligations375.3 K395.1 K952.1 K
Slightly volatile
Non Current Liabilities Other863.6 K707.4 K983.6 K
Slightly volatile
Other Liabilities1.9 M2.1 M2.3 M
Slightly volatile
Long Term Debt108.6 M117.9 M96.4 M
Slightly volatile
Long Term Debt Total74.4 M83.7 M91.4 M
Slightly volatile

BioXcel Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative27.2 M38.1 M18.5 M
Slightly volatile
Other Operating Expenses71.8 M79.9 M47.5 M
Slightly volatile
Research Development39.8 M35 M25.7 M
Slightly volatile
Total Operating Expenses71.4 M77.5 M47.1 M
Slightly volatile
Depreciation And Amortization331.8 K278.1 K1 M
Slightly volatile
Interest Income1.8 M3 M1 M
Slightly volatile
Reconciled Depreciation222.2 K355.4 K129.4 K
Slightly volatile
Selling And Marketing Expenses1.5 M1.6 M3.2 M
Slightly volatile
Non Operating Income Net Other2.5 M2.4 M693.2 K
Slightly volatile

BioXcel Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities64.6 M42.2 M40.9 M
Slightly volatile
Stock Based Compensation10.3 M7.1 M6.2 M
Slightly volatile
Change To Netincome22.4 M21.3 M8.6 M
Slightly volatile
Change To Liabilities20.3 M19.4 M6.3 M
Slightly volatile
End Period Cash Flow32.6 M34.3 M52 M
Slightly volatile
Issuance Of Capital Stock59.4 M35.7 M62.8 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.317.691.2 K
Slightly volatile
Days Sales Outstanding23.0524.27190
Slightly volatile
Stock Based Compensation To Revenue2.973.1236.6654
Slightly volatile
Capex To Depreciation0.06870.07233.5083
Slightly volatile
EV To Sales42.5544.791 K
Slightly volatile
Inventory Turnover2.982.840.5729
Slightly volatile
Days Of Inventory On Hand12613327.8 K
Slightly volatile
Payables Turnover0.130.120.0391
Slightly volatile
Sales General And Administrative To Revenue15.9616.8119
Slightly volatile
Research And Ddevelopement To Revenue14.6715.45192
Slightly volatile
Capex To Revenue0.01580.01670.2871
Slightly volatile
Cash Per Share10.0710.633.1174
Slightly volatile
Days Payables Outstanding3 K3.1 K20.6 K
Slightly volatile
Income Quality0.61.090.6718
Slightly volatile
Current Ratio1.441.513.5116
Slightly volatile
Receivables Turnover10.215.574.833
Slightly volatile
Capex Per Share0.0120.01260.1318
Pretty Stable
Revenue Per Share0.50.80.3374
Slightly volatile
Interest Debt Per Share44.0241.9215.3532
Slightly volatile
Debt To Assets2.542.420.6905
Slightly volatile
Operating Cycle14915727.9 K
Slightly volatile
Days Of Payables Outstanding3 K3.1 K20.6 K
Slightly volatile
Ebt Per Ebit1.091.021.0023
Pretty Stable
Effective Tax Rate0.00270.0030.0033
Slightly volatile
Long Term Debt To Capitalization10.39.812.3772
Slightly volatile
Quick Ratio1.411.493.4991
Slightly volatile
Net Income Per E B T0.790.90.9695
Slightly volatile
Cash Ratio1.471.543.5652
Slightly volatile
Days Of Inventory Outstanding12613327.8 K
Slightly volatile
Days Of Sales Outstanding23.0524.27190
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0222
Slightly volatile
Fixed Asset Turnover2.52.380.6369
Slightly volatile
Debt Ratio2.542.420.6905
Slightly volatile
Price Sales Ratio7.317.691.2 K
Slightly volatile
Asset Turnover0.05590.05320.0124
Slightly volatile
Gross Profit Margin0.05930.06240.7394
Slightly volatile

BioXcel Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap13 M13.6 M234.1 M
Very volatile
Enterprise Value104.4 M109.9 M219.3 M
Very volatile

BioXcel Fundamental Market Drivers

BioXcel Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioXcel Therapeutics Financial Statements

Investors use fundamental indicators, such as BioXcel Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although BioXcel Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue133.4 K126.7 K
Total Revenue2.6 M2.7 M
Cost Of Revenue2.5 M2.6 M
Stock Based Compensation To Revenue 3.12  2.97 
Sales General And Administrative To Revenue 16.80  15.96 
Research And Ddevelopement To Revenue 15.45  14.67 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.80  0.50 
Ebit Per Revenue(26.71)(28.04)

Currently Active Assets on Macroaxis

MSFTMicrosoft
DDDupont De Nemours
WDWalker Dunlop
GOOGAlphabet Inc Class C
CRMSalesforce
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:
How To Invest In BioXcel
Details
Is BioXcel Stock a good investment?
Details
What is BioXcel Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of BioXcel Therapeutics Correlation against competitors.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is there potential for Biotechnology market expansion? Will BioXcel introduce new products? Factors like these will boost the valuation of BioXcel Therapeutics. Projected growth potential of BioXcel fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.12)
Revenue Per Share
0.1
Quarterly Revenue Growth
(0.54)
Return On Assets
(0.67)
Return On Equity
(17.67)
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between BioXcel Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioXcel Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioXcel Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY